Evercore ISI Group Maintains Outperform on NovoCure, Raises Price Target to $20

Benzinga Newsdesk www.benzinga.com Positive 90.4%

Neg 0% Neu 0% Pos 90.4%

Evercore ISI Group analyst Vijay Kumar maintains NovoCure (NASDAQ:NVCR) with a Outperform and raises the price target from $16 to $20.